Determination of the most influential sources of variability in tacrolimus trough blood concentrations in adult liver transplant recipients: A bottom-up approach

AAPS Journal

Volumn 16, Issue 3, 2014, Pages 379-391

  Gérard, Cécile ^a   Stocco, Jeanick ^b   Hulin, Anne ^c   Blanchet, Benoit ^d   Verstuyft, Céline ^e   Durand, François ^b   Conti, Filomena ^f   Duvoux, Christophe ^c,g   Tod, Michel ^a,h  

^a UNIVERSITÉ CLAUDE BERNARD LYON 1   (France)

^b BEAUJON HOSPITAL   (France)

^c HENRI MONDOR HOSPITAL   (France)

^d Institut Cochin   (France)

^e BICÊTRE HOSPITAL   (France)

^f HÔPITAL SAINT ANTOINE   (France)

^g UNIVERSITÉ PARIS EST CRÉTEIL   (France)

^h CROIX ROUSSE HOSPITAL   (France)

Author keywords

bottom up approach; liver transplantation; tacrolimus; therapeutic drug monitoring

Indexed keywords

AMIODARONE; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; FLUCONAZOLE; MIDAZOLAM; NICARDIPINE; TACROLIMUS; VORICONAZOLE; CYP3A5 PROTEIN, HUMAN; CYTOCHROME P450 3A; IMMUNOSUPPRESSIVE AGENT;

ADIPOSE TISSUE; ADULT; ARTICLE; BODY WEIGHT; DISTRIBUTION VOLUME; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG TROUGH BLOOD CONCENTRATION; GENETIC POLYMORPHISM; HEMATOCRIT; HUMAN; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; PHARMACOGENOMICS; SIMULATION; AGED; BLOOD; FEMALE; GENOTYPE; INTESTINE ABSORPTION; MALE; METABOLISM; MIDDLE AGED; PHARMACOGENETICS; PROCEDURES; PROSPECTIVE STUDY;

ADULT; AGED; BODY WEIGHT; CYTOCHROME P-450 CYP3A; FEMALE; GENOTYPE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTESTINAL ABSORPTION; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PHARMACOGENETICS; PROSPECTIVE STUDIES; TACROLIMUS;

EID: 84900330189     PISSN: None     EISSN: 15507416     Source Type: Journal    
DOI: 10.1208/s12248-014-9577-8     Document Type: Article

References (61)

1. Kino T, Hatanaka H, Hashimoto M, Nishiyama M, Goto T, Okuhara M, et al. FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physicochemical and biological characteristics. J Antibiot (Tokyo). 1987;40(9):1249-55. (Pubitemid 17138109)
2. Kino T, Hatanaka H, Miyata S, Inamura N, Nishiyama M, Yajima T, et al. FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro. J Antibiot (Tokyo). 1987;40(9):1256-65. (Pubitemid 17138110)
3. Venkataramanan R, Swaminathan A, Prasad T, Jain A, Zuckerman S, Warty V, et al. Clinical pharmacokinetics of tacrolimus. Clin Pharmacokinet. 1995;29(6):404-30. (Pubitemid 26004179)
4. Wong SH. Therapeutic drug monitoring for immunosuppressants. Clin Chim Acta. 2001;313(1-2):241-53. (Pubitemid 33016717)
5. Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. Clin Pharmacokinet. 2004;43(10):623-53. (Pubitemid 38981845)
6. Wallemacq P, Armstrong VW, Brunet M, Haufroid V, Holt DW, Johnston A, et al. Opportunities to optimize tacrolimus therapy in solid organ transplantation: report of the European consensus conference. Ther Drug Monit. 2009;31(2):139-52.
7. Rodriguez-Peralvarez M, Germani G, Darius T, Lerut J, Tsochatzis E, Burroughs AK. Tacrolimus trough levels, rejection and renal impairment in liver transplantation: a systematic review and meta-analysis. Am J Transplant. 2012;12(10):2797-814.
8. Rodriguez-Peralvarez M, Germani G, Papastergiou V, Tsochatzis E, Thalassinos E, Luong TV, et al. Early tacrolimus exposure after liver transplantation: relationship with moderate/severe acute rejection and long-term outcome. J Hepatol. 2012 Sep 27.
9. Backman L, Nicar M, Levy M, Distant D, Eisenstein C, Renard T, et al. FK506 trough levels in whole blood and plasma in liver transplant recipients. Correlation with clinical events and side effects. Transplantation. 1994;57(4):519-25. (Pubitemid 24075796)
10. Venkataramanan R, Shaw LM, Sarkozi L, Mullins R, Pirsch J, MacFarlane G, et al. Clinical utility of monitoring tacrolimus blood concentrations in liver transplant patients. J Clin Pharmacol. 2001;41(5):542-51. (Pubitemid 32381872)
11. Staatz CE, Goodman LK, Tett SE. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: part I. Clin Pharmacokinet. 2010;49(3):141-75.
12. Fukudo M, Yano I, Masuda S, Goto M, Uesugi M, Katsura T, et al. Population pharmacokinetic and pharmacogenomic analysis of tacrolimus in pediatric living-donor liver transplant recipients. Clin Pharmacol Ther. 2006;80(4):331-45. (Pubitemid 44479749)
13. Hesselink DA, van Schaik RH, van der Heiden IP, van der Werf M, Gregoor PJ, Lindemans J, et al. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther. 2003;74(3):245-54. (Pubitemid 37083100)
14. Thervet E, Anglicheau D, King B, Schlageter MH, Cassinat B, Beaune P, et al. Impact of cytochrome p450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients. Transplantation. 2003;76(8):1233-5. (Pubitemid 37339651)
15. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet. 2001;27(4):383-91. (Pubitemid 32268418)
16. Blanco JG, Edick MJ, Hancock ML, Winick NJ, Dervieux T, Amylon MD, et al. Genetic polymorphisms in CYP3A5, CYP3A4 and NQO1 in children who developed therapy-related myeloid malignancies. Pharmacogenetics. 2002;12(8):605-11. (Pubitemid 36005669)
17. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmoller J, Johne A, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A. 2000;97(7):3473-8. (Pubitemid 30183327)
18. Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, Gottesman MM. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol. 1999;39:361-98. (Pubitemid 29222564)
19. Saeki T, Ueda K, Tanigawara Y, Hori R, Komano T. Human P-glycoprotein transports cyclosporin A and FK506. J Biol Chem. 1993;268(9):6077-80. (Pubitemid 23099291)
20. Staatz CE, Taylor PJ, Lynch SV, Willis C, Charles BG, Tett SE. Population pharmacokinetics of tacrolimus in children who receive cut-down or full liver transplants. Transplantation. 2001;72(6):1056-61. (Pubitemid 32924077)
21. Fukudo M, Yano I, Fukatsu S, Saito H, Uemoto S, Kiuchi T, et al. Forecasting of blood tacrolimus concentrations based on the Bayesian method in adult patients receiving living-donor liver transplantation. Clin Pharmacokinet. 2003;42(13):1161-78. (Pubitemid 37357651)
22. Staatz CE, Willis C, Taylor PJ, Lynch SV, Tett SE. Toward better outcomes with tacrolimus therapy: population pharmacokinetics and individualized dosage prediction in adult liver transplantation. Liver Transpl. 2003;9(2):130-7. (Pubitemid 36204563)
23. Antignac M, Hulot JS, Boleslawski E, Hannoun L, Touitou Y, Farinotti R, et al. Population pharmacokinetics of tacrolimus in full liver transplant patients: modelling of the post-operative clearance. Eur J Clin Pharmacol. 2005;61(5-6):409-16. (Pubitemid 41569318)
24. Blanchet B, Duvoux C, Costentin CE, Barrault C, Ghaleh B, Salvat A, et al. Pharmacokinetic-pharmacodynamic assessment of tacrolimus in liver-transplant recipients during the early post-transplantation period. Ther Drug Monit. 2008;30(4):412-8.
25. Yano I, Masuda S, Egawa H, Sugimoto M, Fukudo M, Yoshida Y, et al. Significance of trough monitoring for tacrolimus blood concentration and calcineurin activity in adult patients undergoing primary living-donor liver transplantation. Eur J Clin Pharmacol. 2012;68(3):259-66.
26. de Jonge H, de Loor H, Verbeke K, Vanrenterghem Y, Kuypers DR. In vivo CYP3A4 activity, CYP3A5 genotype, and hematocrit predict tacrolimus dose requirements and clearance in renal transplant patients. Clin Pharmacol Ther. 2012;92(3):366-75.
27. Jamei M, Dickinson GL, Rostami-Hodjegan A. A framework for assessing inter-individual variability in pharmacokinetics using virtual human populations and integrating general knowledge of physical chemistry, biology, anatomy, physiology and genetics: a tale of 'bottom-up' vs 'top-down' recognition of covariates. Drug Metab Pharmacokinet. 2009;24(1):53-75.
28. Ohtani H, Barter Z, Minematsu T, Makuuchi M, Sawada Y, Rostami-Hodjegan A. Bottom-up modeling and simulation of tacrolimus clearance: prospective investigation of blood cell distribution, sex and CYP3A5 expression as covariates and assessment of study power. Biopharm Drug Dispos. 2011;32(9):498-506.
29. Lavielle M. MONOLIX (MOdèles NOn LInéaires à effets miXtes). Orsay: MONOLIX group; 2008.
30. Mandema JW, Verotta D, Sheiner LB. Building population pharmacokinetic-pharmacodynamic models. I. Models for covariate effects. J Pharmacokinet Biopharm. 1992;20(5):511-28. (Pubitemid 23034413)
31. Levitt DG. PKQuest: a general physiologically based pharmacokinetic model. Introduction and application to propranolol. BMC Clin Pharmacol. 2002;2:5.
32. Levitt DG, Schnider TW. Human physiologically based pharmacokinetic model for propofol. BMC Anesthesiol. 2005;5(1):4.
33. Pang KS, Rowland M. Hepatic clearance of drugs. I. Theoretical considerations of a "well-stirred" model and a "parallel tube" model. Infl uence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance. J Pharmacokinet Biopharm. 1977;5(6):625-53. (Pubitemid 8253670)
34. Tacrolimus. 2012 [updated 2012; cited May 22, 2012]; Available from: http://www.drugbank.ca/drugs/DB00864.
35. Jusko WJ, Piekoszewski W, Klintmalm GB, Shaefer MS, Hebert MF, Piergies AA, et al. Pharmacokinetics of tacrolimus in liver transplant patients. Clin Pharmacol Ther. 1995;57(3):281-90.
36. Zahir H, Nand RA, Brown KF, Tattam BN, McLachlan AJ. Validation of methods to study the distribution and protein binding of tacrolimus in human blood. J Pharmacol Toxicol Methods. 2001;46(1):27-35. (Pubitemid 34260893)
37. Ohno Y, Hisaka A, Suzuki H. General framework for the quantitative prediction of CYP3A4-mediated oral drug interactions based on the AUC increase by coadministration of standard drugs. Clin Pharmacokinet. 2007;46(8):681-96. (Pubitemid 47204854)
38. Satoh S, Kagaya H, Saito M, Inoue T, Miura M, Inoue K, et al. Lack of tacrolimus circadian pharmacokinetics and CYP3A5 pharmacogenetics in the early and maintenance stages in Japanese renal transplant recipients. Br J Clin Pharmacol. 2008;66(2):207-14.
39. Dai Y, Hebert MF, Isoherranen N, Davis CL, Marsh C, Shen DD, et al. Effect of CYP3A5 polymorphism on tacrolimus metabolic clearance in vitro. Drug Metab Dispos. 2006;34(5):836-47.
40. Mori T, Aisa Y, Kato J, Nakamura Y, Ikeda Y, Okamoto S. Drug interaction between oral solution itraconazole and calcineurin inhibitors in allogeneic hematopoietic stem cell transplantation recipients: an association with bioavailability of oral solution itraconazole. Int J Hematol. 2009;90(1):103-7.
41. Sansone-Parsons A, Krishna G, Martinho M, Kantesaria B, Gelone S, Mant TG. Effect of oral posaconazole on the pharmacokinetics of cyclosporine and tacrolimus. Pharmacotherapy. 2007;27(6):825-34. (Pubitemid 46849426)
42. Christians U, Jacobsen W, Benet LZ, Lampen A. Mechanisms of clinically relevant drug interactions associated with tacrolimus. Clin Pharmacokinet. 2002;41(11):813-51.
43. Deurenberg P, Weststrate JA, Seidell JC. Body mass index as a measure of body fatness: age- and sex-specific prediction formulas. Br J Nutr. 1991;65(2):105-14.
44. D'Argenio D, Schumitzky A. ADAPT II user's guide. Pharmacokinetic/ Pharmacodynamic Systems Analysis Software. Los Angeles: Biomedical Simulations Resource; 1997.
45. Pilari S, Huisinga W. Lumping of physiologically-based pharmacokinetic models and a mechanistic derivation of classical compartmental models. J Pharmacokinet Pharmacodyn. 2010;37(4):365-405.
46. Wilkinson GR, Shand DG. Commentary: a physiological approach to hepatic drug clearance. Clin Pharmacol Ther. 1975;18(4):377-90.
47. Capron A, Lerut J, Latinne D, Rahier J, Haufroid V, Wallemacq P. Correlation of tacrolimus levels in peripheral blood mononuclear cells with histological staging of rejection after liver transplantation: preliminary results of a prospective study. Transpl Int. 2011;25(1):41-7.
48. Fukatsu S, Yano I, Igarashi T, Hashida T, Takayanagi K, Saito H, et al. Population pharmacokinetics of tacrolimus in adult recipients receiving living-donor liver transplantation. Eur J Clin Pharmacol. 2001;57(6-7):479-84.
49. Provenzani A, Notarbartolo M, Labbozzetta M, Poma P, Vizzini G, Salis P, et al. Infl uence of CYP3A5 and ABCB1 gene polymorphisms and other factors on tacrolimus dosing in Caucasian liver and kidney transplant patients. Int J Mol Med. 2011;28(6):1093-102.
50. Li D, Lu W, Zhu JY, Gao J, Lou YQ, Zhang GL. Population pharmacokinetics of tacrolimus and CYP3A5, MDR1 and IL-10 polymorphisms in adult liver transplant patients. J Clin Pharm Ther. 2007;32(5):505-15. (Pubitemid 47404287)
51. Fukudo M, Yano I, Yoshimura A, Masuda S, Uesugi M, Hosohata K, et al. Impact of MDR1 and CYP3A5 on the oral clearance of tacrolimus and tacrolimus-related renal dysfunction in adult living-donor liver transplant patients. Pharmacogenet Genomics. 2008;18(5):413-23. (Pubitemid 351535942)
52. Shimada T, Terada A, Yokogawa K, Kaneko H, Nomura M, Kaji K, et al. Lowered blood concentration of tacrolimus and its recovery with changes in expression of CYP3A and P-glycoprotein after high-dose steroid therapy. Transplantation. 2002;74(10):1419-24. (Pubitemid 35379549)
53. Kuypers DR, Claes K, Evenepoel P, Maes B, Coosemans W, Pirenne J, et al. Time-related clinical determinants of long-term tacrolimus pharmacokinetics in combination therapy with mycophenolic acid and corticosteroids: a prospective study in one hundred de novo renal transplant recipients. Clin Pharmacokinet. 2004;43(11):741-62. (Pubitemid 39159005)
54. Zahir H, McCaughan G, Gleeson M, Nand RA, McLachlan AJ. Factors affecting variability in distribution of tacrolimus in liver transplant recipients. Br J Clin Pharmacol. 2004;57(3):298-309. (Pubitemid 38296993)
55. Burns AM, Shelly MP, Walker S, Park GR. Serum acute phase proteins after orthotopic liver transplantation. Br J Anaesth. 1990;65(3):418-20. (Pubitemid 20275630)
56. Abu-Elmagd K, Fung JJ, Alessiani M, Jain A, Venkataramanan R, Warty VS, et al. The effect of graft function on FK506 plasma levels, dosages, and renal function, with particular reference to the liver. Transplantation. 1991;52(1):71-7.
57. Jain AB, Abu-Elmagd K, Abdallah H, Warty V, Fung J, Todo S, et al. Pharmacokinetics of FK506 in liver transplant recipients after continuous intravenous infusion. J Clin Pharmacol. 1993;33(7):606-11. (Pubitemid 23215547)
58. Winkler M, Ringe B, Rodeck B, Melter M, Stoll K, Baumann J, et al. The use of plasma levels for FK 506 dosing in liver-grafted patients. Transpl Int. 1994;7(5):329-33. (Pubitemid 24261022)
59. Arroyo M, Rocandio AM, Ansotegui L, Herrera H, Salces I, Rebato E. Comparison of predicted body fat percentage from anthropometric methods and from impedance in university students. Br J Nutr. 2004;92(5):827-32. (Pubitemid 39562162)
60. VIDAL. PROGRAF® Gélules [database on the Internet]. 2012 [cited 03/08/2012]. Available from: http://www.vidalpro.net/medicaments/front/ recherchemedic.asp?site=2&cartouche=17&id=41863&lib= PROGRAF+1+mg+g%E9l+%3A+Plq%2F50&type=spe.
61. Thervet E, Loriot MA, Barbier S, Buchler M, Ficheux M, Choukroun G, et al. Optimization of initial tacrolimus dose using pharmacogenetic testing. Clin Pharmacol Ther. 2010;87(6):721-6.